Search results for: Adrian Towse
Filter search results
OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme
10 December 2014
…OHE’s Adrian Towse. In the BMJ blog post “Why has the PROMs programme stalled?” (3rd December 2014), Nancy Devlin, John Appleby, and David Parkin argue that the PROMs programme,…
Recently published: Are Wider Societal Effects Considered in Healthcare Decision-making?
29 February 2016
…by OHE’s Martina Garau, Koonal Shah, and Adrian Towse. There is evidence suggesting that, in certain diseases areas such as Alzheimer’s disease, depression, and breast cancer, health interventions can produce…
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
…Ferraro, Phill O’Neill and Adrian Towse. Read the full report here. Citation Ferraro, J. S., O’Neill, P. & Towse, A. 2018. Measurement of Medicines Expenditure in the Context of the…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
…of healthcare spending in rich and poorer markets alike. In this blog post, Kalipso Chalkidou and Adrian Towse discuss a new OHE Research Paper, published in collaboration with the Center…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…the second of two blog posts, Kalipso Chalkidou and Adrian Towse discuss a new OHE Research Paper, published in collaboration with the Center for Global Development (CGD). Our review of…
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
1 April 2020
…Development website, co-authored by Rachel Silverman, Carleigh Krubiner, Kalipso Chalkidou and Adrian Towse, discusses options to fund a vaccine against COVID-19. The Note points out that global leaders are realizing…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
…Center) and Adrian Towse takes the recent ISPOR Special Task Force (STF) as the starting point and focuses on those aspects of the ‘value flower’ related to uncertainty. Even though…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…Lou Garrison, Aig Unuigbe and Adrian Towse look at the theoretical equivalence of these two approaches. The MCDA model uses a multi-attribute utility function. The ACEA model is based on…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…price” has spurred recent efforts to understand both the root causes of the problem, what actually needs to be solved, and by whom. This publication by authors from OHE (Adrian…